Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07504172

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice.

In this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are:

* How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching? * How is the medication dosed in daily practice? Researchers will use data from electronic health records of patients in multiple outpatient locations of the Dutch Obesity Clinic (NOK, Nederlandse Obesitas Kliniek).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Overweight , Obesity Body Weight Body Weight Changes Nutrition Disorders Nutritional and Metabolic Diseases Obesity Obesity (Disorder) Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms Weight Loss

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

NOK clinics, Amsterdam, Netherlands

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (age ≥18 years old)
  • A BMI of ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one obesity complication (e.g., hypertension, dyslipidaemia)

Exclusion criteria

  • Pregnant women or pregnancy during treatment
  • Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery)
  • Patients with diabetes

Treatment and study plan

Tirzepatide

Drug

Initiating treatment with tirzepatide

Other names: Mounjaro

Primary outcomes

  1. Weight change

    Time frame: Baseline-6 months

    %TWL= (start weight - 6 month weight/baseline weight)*100%

Secondary outcomes

  1. Changes in body composition

    Time frame: Basline-6 months

    Fat percentage (FP) and fat free mass (FFM)

  2. Demographic and clinical characteristics

    Time frame: Baseline

    • Age
    • Gender
    • Treatment location
    • Obesity associated diseases: hypertension, dyslipidaemia, sleep apnoea and osteoarthritis
    • Previous lifestyle treatment for obesity

  3. Weight loss by maintenance dose

    Time frame: Baseline-6 months

    Maintenance dose (10mg and 15mg)

  4. Tirzepatide dosing patterns

    Time frame: Baseline-6 months

    Including the initial prescribed dose and subsequent dose escalations throughout the treatment course

  5. Weigth

    Time frame: Baseline-6 months

    in kilograms (kg)

  6. Height

    Time frame: Baseline-6 months

    in centimeters (cm)

Study contacts

Contact information is provided by the study sponsor or research team.

Puck van den Hooff, MD

CONTACT

[email protected]

+31649653657

Valerie Monpellier, MD, PhD

CONTACT

[email protected]

+31645247665

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Nederlandse Obesitas Kliniek

Registry information

Official study title

Real-world Effectiveness and Dosing Patterns of Tirzepatide: A Multicentre Retrospective Observational Study in the Netherlands

Acronym: TIRZ-DOSE-NL

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 31, 2026
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.